NL-OMON34733招募中不适用
Comparison of three Plasmodium falciparum isolates in an experimental human malaria infection - TIP1
niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 15 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Age > 18 and < 35 years healthy volunteers (males or females)
- •2. General good health based on history and clinical examination
- •3. Negative pregnancy test
- •4. Use of adequate contraception for females
- •5. All volunteers have to sign the informed consent form following proper understanding of the meaning and procedures of the study
- •6. Volunteer agrees to inform the general practitioner and agrees to sign a request for medical information concerning contra-indications for participation in the study
- •7. Willingness to undergo a Pf sporozoite challenge
- •8. Agreement to stay in a hotel room close to the trial center during a part of the study (Day 5 till Day T +3)
- •9. Reachable by mobile phone during the whole study period
- •10. Available to attend all study visits
- •11. Agreement to refrain from blood donation to Sanquin or for other purposes, during the course of the study
- •12. Willingness to undergo an HIV, hepatitis B and C test
- •13. Negative urine toxicology screening test at screening visit and day before challenge
- •14. Willingness to take a curative regimen of Malarone®
排除标准
- •1. History of malaria
- •2. Plans to travel to endemic malaria areas during the study period
- •3. Plans to travel outside of the Netherlands during day 0-28 of the study
- •4. Previous participation in any malaria vaccine study and/or positive serology for Pf
- •5. Symptoms, physical signs and laboratory values suggestive of systemic disorders, including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric and other conditions, which could interfere with the interpretation of the study results or compromise the health of the volunteers
- •6. History of diabetes mellitus or cancer (except basal cell carcinoma of the skin)
- •7. History of arrhythmia*s or prolonged QT-interval
- •8. Positive family history in 1st and 2nd degree relatives for cardiac disease < 50 years old
- •9. An estimated, ten year risk of fatal cardiovascular disease of >=5%, as estimated by the Systematic Coronary Risk Evaluation (SCORE) system
- •10. Body Mass Index (BMI) below 18 or above 30 kg/m2
- •11. Any clinically significant deviation from the normal range in biochemistry or haematology blood tests or in urine analysis
- •12. Positive HIV, HBV or HCV tests
- •13. Participation in any other clinical study within 30 days prior to the onset of the study
- •14. Volunteers enrolled in any other clinical study during the study period
- •15. Pregnant or lactating women
- •16. Volunteers unable to give written informed consent
- •17. Volunteers unable to be closely followed for social, geographic or psychological reasons
- •18. Previous history of drug or alcohol abuse interfering with normal social function during a period of one year prior to enrolment in the study
- •19. A history of psychiatric disease
- •20. Known hypersensitivity for anti-malaria drugs
- •21. History of severe reactions or allergy to mosquito bites
- •22. The use of chronic immunosuppressive drugs, antibiotics, or other immune modifying drugs within three months before study onset (inhaled and topical corticosteroids are allowed) and during the study period
- •23. Contra-indications to Malarone® including treatment taken by the volunteers that interfere with Malarone®
- •24. Any confirmed or suspected immunosuppressive or immunodeficiency condition, including asplenia
- •25. Co-workers of the departments of Medical Microbiology or Internal Medicine of the Radboud University Nijmegen Medical Centre or Leiden University Medical Center
- •26. A history of sickle cell, thalasaemia trait and G6PD deficiency
研究者
相似试验
已完成
不适用
Comparison of three Plasmodium falciparum isolates in a controlled human malaria infectiomalariaNL-OMON37044niversitair Medisch Centrum Sint Radboud15
招募中
不适用
Gene variations in malaria related to Infection, Transmission and Drug responseCTRI/2020/11/029211Manipal Academy of Higher Education
已完成
不适用
Efficacy of artemether-lumefantrine treatment in uncomplicated malaria (Plasmodium falciparum) patients and in-vitro experiment on susceptibility of malaria (P. falciparum) strains to new chemical substancesISRCTN08391109Medicines for Malaria Venture (MMV) (Switzerland)110
尚未招募
不适用
Evaluation of population diversity of Plasmodium falciparum isolates from children with uncomplicated infection during the adoption of artemisinin-based combination therapy in NigeriaMalariaPACTR202106708800075Kazeem Akano75
已完成
不适用
Immunization with different numbers of Plasmodium falciparum infected mosquito-bites under chloroquine prophylaxisPlasmodium falciparum10037072MalariaNL-OMON36588niversitair Medisch Centrum Sint Radboud30